Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00506779 · ClinicalTrials.gov registry record · Phase 1
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00506779: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00506779 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00506779, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Objectives: * To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma. * To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in this cohort of patients. * To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either c-Kit, PDGFR or abl.
Interventions
- DRUG Paclitaxel
- DRUG Imatinib Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2003-12-29 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00506779
The ClinicalTrials.gov registry entry for NCT00506779 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT00506779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00506779 about?
NCT00506779 is a clinical study titled "Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma". Objectives: * To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma. * To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in this co...
What is the current status of trial NCT00506779?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2003-12-29. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00506779?
The interventions under investigation include: Paclitaxel (DRUG), Imatinib Mesylate (DRUG).
Who is sponsoring clinical trial NCT00506779?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.